Trial of varenicline (Champix) for the treatment of spinocerebellar degeneration - Varenicline trial for SCD

iigata University0 个研究点目标入组 40 人开始时间: 2013年8月26日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) any unstable illness or concomitant medical condition that precluded participation in this study, including other disorders that may affect gait or balance (stroke, arthritis, or others) 2) pregnancy or lactation 3) smoking at the time of screening or within the past 12 months 4) concurrent treatment with monoamine oxidase inhibitors, bupropion, or nicotine patches 5) dementia or other psychiatric illness (including psychosis, bipolar disorder, untreated depression (Beck Depression Inventory score 21), or history of suicide attempt) or any other illness that would have precluded a patient from giving informed consent (Mini-Mental State Examination score 24) 6) use of varenicline within the previous 30 days 7) ataxia derived from any cause other than genetically confirmed SCA and CCA (including but not limited to alcoholism, head injury, multiple sclerosis, and multiple system atrophy)

发起方

iigata University